Logo image of HSKA

Heska Corporation (HSKA) Stock Fundamental Analysis

NASDAQ:HSKA - Nasdaq - US42805E3062 - Common Stock - Currency: USD

119.99  +0.05 (+0.04%)

After market: 119.99 0 (0%)

Fundamental Rating

3

HSKA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. HSKA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSKA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year HSKA has reported negative net income.
HSKA had a negative operating cash flow in the past year.
HSKA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: HSKA reported negative operating cash flow in multiple years.
HSKA Yearly Net Income VS EBIT VS OCF VS FCFHSKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

1.2 Ratios

HSKA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSKA Yearly ROA, ROE, ROICHSKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5 -5 10

1.3 Margins

The Gross Margin of HSKA (42.93%) is worse than 62.02% of its industry peers.
HSKA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for HSKA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y-0.85%
HSKA Yearly Profit, Operating, Gross MarginsHSKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40

5

2. Health

2.1 Basic Checks

HSKA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HSKA has more shares outstanding
HSKA has a better debt/assets ratio than last year.
HSKA Yearly Shares OutstandingHSKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
HSKA Yearly Total Debt VS Total AssetsHSKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

HSKA has an Altman-Z score of 4.79. This indicates that HSKA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.79, HSKA is in the better half of the industry, outperforming 75.48% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that HSKA is not too dependend on debt financing.
HSKA has a Debt to Equity ratio (0.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 4.79
ROIC/WACCN/A
WACC9.05%
HSKA Yearly LT Debt VS Equity VS FCFHSKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.64 indicates that HSKA has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.64, HSKA is doing good in the industry, outperforming 70.67% of the companies in the same industry.
A Quick Ratio of 4.12 indicates that HSKA has no problem at all paying its short term obligations.
The Quick ratio of HSKA (4.12) is better than 68.27% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.12
HSKA Yearly Current Assets VS Current LiabilitesHSKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

3

3. Growth

3.1 Past

HSKA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.97%.
HSKA shows a decrease in Revenue. In the last year, the revenue decreased by -1.22%.
HSKA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.75% yearly.
EPS 1Y (TTM)-51.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-1.22%
Revenue growth 3Y28%
Revenue growth 5Y14.75%
Sales Q2Q%-3.73%

3.2 Future

HSKA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.44% yearly.
Based on estimates for the next years, HSKA will show a small growth in Revenue. The Revenue will grow by 7.79% on average per year.
EPS Next Y55.25%
EPS Next 2Y40.17%
EPS Next 3Y27.58%
EPS Next 5Y26.44%
Revenue Next Year9.92%
Revenue Next 2Y9.98%
Revenue Next 3Y9.67%
Revenue Next 5Y7.79%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HSKA Yearly Revenue VS EstimatesHSKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
HSKA Yearly EPS VS EstimatesHSKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2 3

1

4. Valuation

4.1 Price/Earnings Ratio

HSKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSKA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSKA Price Earnings VS Forward Price EarningsHSKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSKA Per share dataHSKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

HSKA's earnings are expected to grow with 27.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.17%
EPS Next 3Y27.58%

0

5. Dividend

5.1 Amount

HSKA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

Heska Corporation

NASDAQ:HSKA (6/12/2023, 8:00:01 PM)

After market: 119.99 0 (0%)

119.99

+0.05 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-05 2023-05-05/bmo
Earnings (Next)08-07 2023-08-07/bmo
Inst Owners0.01%
Inst Owner Change0%
Ins Owners3.86%
Ins Owner Change0%
Market Cap1.31B
Analysts78
Price Target132.6 (10.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.3
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-496.61%
Min EPS beat(2)-904.9%
Max EPS beat(2)-88.31%
EPS beat(4)1
Avg EPS beat(4)-332.9%
Min EPS beat(4)-904.9%
Max EPS beat(4)49.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.2%
Min Revenue beat(2)-4.99%
Max Revenue beat(2)0.58%
Revenue beat(4)1
Avg Revenue beat(4)-5.85%
Min Revenue beat(4)-11.47%
Max Revenue beat(4)0.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-233.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.14
P/FCF N/A
P/OCF N/A
P/B 3.14
P/tB 6.34
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS23.35
BVpS38.27
TBVpS18.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.93%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y-0.85%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 4.12
Altman-Z 4.79
F-Score4
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)11.41%
Cap/Depr(5y)28.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y55.25%
EPS Next 2Y40.17%
EPS Next 3Y27.58%
EPS Next 5Y26.44%
Revenue 1Y (TTM)-1.22%
Revenue growth 3Y28%
Revenue growth 5Y14.75%
Sales Q2Q%-3.73%
Revenue Next Year9.92%
Revenue Next 2Y9.98%
Revenue Next 3Y9.67%
Revenue Next 5Y7.79%
EBIT growth 1Y-43.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year269.41%
EBIT Next 3Y72.39%
EBIT Next 5YN/A
FCF growth 1Y-461.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-344.65%
OCF growth 3YN/A
OCF growth 5YN/A